Communiqués Tempus AI, Inc. Mexican S.E.

Actions

TEM *

US88023B1035

Recherche biotechnologique et médicale

Cours en clôture Mexican S.E. Autres places de cotation 06/08/2026			Varia. 5j.	Varia. 1 janv.
800,00 ^MXN	-1,60%		+5,96%	-24,60%

06/08	CellCarta Inc. et Tempus AI, Inc. concluent une collaboration stratégique pour le réseau de laboratoires de commercialisation de diagnostics compagnons	CI
06/08	Tempus AI : un dirigeant cède pour 1 100 076 $ d'actions, selon un document de la SEC	MT

Communiqués

04/08	Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications	BU
30/07	Tempus: Q2 Earnings Snapshot	AQ
30/07	Tempus Reports Second Quarter 2026 Results	BU
22/07	Tempus Announces National Launch of OneOme Pharmacogenomics Testing, Advancing Patient Safety and Precision Medicine	BU
20/07	Tempus AI : Acquisition of PSNL Investor Deck	PU
20/07	Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform	BU
16/07	Tempus Highlights Landmark Publication Demonstrating Safe, Real-World Deployment of Paige Prostate AI Suite in the UK National Health Service	BU
09/07	Tempus to Report Second Quarter 2026 Financial Results on July 30	BU
25/06	Tempus Announces Research Collaboration with Angiosarcoma Awareness, Inc. to Uncover Insights on Rare Cancers	BU
11/06	Tempus Announces Multi-Center Validation of AI-Enabled ECG Model for Predicting Atrial Fibrillation Risk Published in Heart Rhythm	BU
10/06	Genetics in Medicine Study Demonstrates How Ambry Genetics ExomeReveal RNA Testing Can Improve Diagnostic Clarity in Exome Testing	AQ
09/06	Genetics in Medicine Open Study Demonstrates How Ambry Genetics’ ExomeReveal® RNA Testing Can Improve Diagnostic Clarity in Exome Testing	BU
05/06	Tempus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference	BU
03/06	Tempus Launches Open-Source Digital Pathology Consortium, Names Yale New Haven Health and Leading Cancer Center as Founding Members	BU
01/06	Tempus Announces the Upcoming Clinical Availability of Its First Whole-Genome Sequencing Assay, xH	BU
31/05	Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development	BU
30/05	Tempus Launches the PRECISION Challenge, a National Program Opening Its Foundation Model Work to the Broader Research Community	BU
30/05	Tempus Introduces ‘Preview’: Bridging the Critical Time Gap Between Diagnostic Order and Definitive Results	BU
29/05	Tempus Announces Initial Results from its Multimodal Foundation Model Efforts for Novel and Scalable Insight Generation in Oncology	BU
29/05	Tempus AI : Investor Day Presentation	PU
29/05	Tempus Receives FDA Approval for Tumor Only xT CDx, Enabling Migration of its Entire DNA Solid Tumor Portfolio	BU
28/05	Tempus Expands Next Platform to Deliver Real-Time Clinical Intelligence and Close Critical Care Gaps Across Oncology	BU
27/05	Tempus Upgrades Its Smart Physician Platform, Hub, with Next-Generation Agentic AI Architecture to Streamline Clinical Workflows	BU
26/05	Tempus Announces 37 Abstracts Accepted for Presentation at the 2026 American Society of Clinical Oncology Annual Meeting	BU
21/05	Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use	BU